Evidence map›Paper›PMID 30249304›Full record

ArticleCancer communications (London, England)2018

Development of a novel method for rapid cloning of shRNA vectors, which successfully knocked down CD44 in mesenchymal triple-negative breast cancer cells.

Lei Zhou, Dandan Sheng, Qiaodan Deng, Dong Wang, Suling Liu

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. CD44 as a tumor biomarker and therapeutic target.Experimental hematology & oncology · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Lei ZhouThe CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science & Technology of China, Hefei, 230027, Anhui, P. R. China.
Dandan ShengThe CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science & Technology of China, Hefei, 230027, Anhui, P. R. China.
Qiaodan DengFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, Shanghai Medical College, Key Laboratory of Breast Cancer in Shanghai, Innovation Center for Cell Signaling Network, Cancer Institutes, Department of Breast Surgery, Fudan University, Shanghai, 200032, P. R. China.
Dong WangThe CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science & Technology of China, Hefei, 230027, Anhui, P. R. China.
Suling LiuFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, Shanghai Medical College, Key Laboratory of Breast Cancer in Shanghai, Innovation Center for Cell Signaling Network, Cancer Institutes, Department of Breast Surgery, Fudan University, Shanghai, 200032, P. R. China. suling@fudan.edu.cn.ORCID 0000-0002-0475-0242
University of Science and Technology of China · CNFudan University · CN

Funding

Fudan University Research Foundation IDH 1340042Ministry of Science and Technology 2015CB553800National Key Research and Development Program of China Stem CellNational Key Research and Development Program of China Translational Research 2016YFA0101202National Natural Science Foundation of China 81530075NSFC 81472741Research Foundation of the Fudan University Shanghai Cancer Center YJRC1603
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FemaleHumansHyaluronan ReceptorsRNA, Small InterferingTriple Negative Breast NeoplasmsCD44 protein, humanHyaluronan ReceptorsRNA, Small Interfering

Identifiers

PMID30249304
PMCPMC6154939
OpenAlexW2891701488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.